← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Tavo Biotherapeutics, Inc
Memphis, TN
$3,193,089
Total funding
4
Grants
Funding over time
peak $1.2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,193,089 · 4
By mechanism
R44$2,081,932 · 1
R43$1,111,157 · 3
Investigators at Tavo Biotherapeutics, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation$1,066,178
R44 · FY2024 · EY
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation$1,015,754
R44 · FY2025 · EY
Neuroprotective Properties of a Novel Glaucoma Drug and Formulation$356,501
R43 · FY2021 · EY
Development of a novel depot delivery system for a glaucoma therapeutic$336,047
R43 · FY2023 · EY
Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma$225,000
R43 · FY2019 · EY
Development of a novel depot delivery system for a glaucoma therapeutic$81,745
R43 · FY2024 · EY
Development of a novel depot delivery system for a glaucoma therapeutic$56,864
R43 · FY2024 · EY
Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma$55,000
R43 · FY2020 · EY